XBiotech launches Phase II axial spondyloarthritis trial of vilamakitug
XBiotech has initiated a Phase II clinical trial evaluating vilamakitug in adults with active axial spondyloarthritis (axSpA), after the company's Investigational New Drug application completed the FDA's 30-day review period without a clinical hold. The clearance authorises US patient enrolment in the V-SPINE study and signals the Austin, Texas-based biotech's formal return to rheumatology after several years focused on other pipeline areas.
Vilamakitug, also designated XB2001, is an IgG4 monoclonal antibody that neutralises interleukin-1α (IL-1α), a proximal pro-inflammatory cytokine implicated in the synovial and entheseal inflammation, bone erosion, and cartilage degradation that characterise spondyloarthritis. XBiotech describes it as a "True Human" antibody derived directly from individuals with natural immunity to IL-1α, without modification, a platform approach the company has pursued across multiple inflammatory indications.
Trial design and endpoints
The V-SPINE study (PT064) is a double-blind, randomised, placebo-controlled trial enroling 150 adults with active axSpA. Participants will receive either 400 mg of vilamakitug or placebo administered as weekly subcutaneous injections over 16 weeks. The primary endpoint is the proportion of participants achieving an ASAS40 response at Week 16, a standard composite measure of clinical improvement used across spondyloarthritis trials. A 12-week open-label extension, in which all participants receive the active drug, follows the blinded period.
The scientific advisory board shaping the protocol includes several prominent US rheumatologists, among them Study Chair Marina Magrey, Division Chief of Rheumatology at University Hospitals Cleveland Medical Center and a leading figure in the Spondyloarthritis Research and Treatment Network (SPARTAN). "The PT064 protocol is rigorously designed to test whether targeting this upstream pathway translates into meaningful clinical benefit," Dr Magrey said in a statement accompanying the announcement.
Sushma Shivaswamy, XBiotech's interim chief executive and chief scientific officer, described FDA clearance as a significant step and said the company intends to move into enrolment quickly.
Market context and competitive landscape
Axial spondyloarthritis, which encompasses both ankylosing spondylitis and non-radiographic axSpA, affects an estimated 1–2% of adults in Western populations and carries a substantial burden of chronic pain and reduced mobility. Approved biologics in the indication include TNF inhibitors from several major manufacturers and IL-17A-targeting agents such as secukinumab and ixekizumab, along with JAK inhibitors that have more recently entered the class. Despite this array of options, a meaningful proportion of patients still fail to achieve adequate disease control, representing the clinical gap vilamakitug is designed to address.
Targeting IL-1α rather than IL-17 or TNF is a mechanistically distinct approach in axSpA. XBiotech itself previously advanced bermekimab, an earlier True Human anti-IL-1α antibody, across multiple inflammatory diseases before selling those rights in a deal worth up to $1.35 billion in 2019. That transaction excluded dermatology rights, and XBiotech retained the ability to develop IL-1α antibodies across all other therapeutic areas, making vilamakitug a direct continuation of that programme rather than a fresh scientific bet.
Whether IL-1α inhibition will demonstrate the clinical effect sizes needed to compete with established agents remains the key question for V-SPINE. The ASAS40 response rate at Week 16 will be closely scrutinised relative to historical benchmarks from IL-17 and JAK inhibitor trials, which have posted ASAS40 rates in the range of 35–40% on placebo and 50–60% on active treatment in broadly similar populations. XBiotech has not disclosed interim or preclinical efficacy data to contextualise expectations.
Topline results from the 16-week blinded phase are the primary near-term catalyst for the company.